Clinical trialPhase 1 / Phase 2Unknown
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
A Phase 1B/2A Trial of CEND-1 in Combination with Neoadjuvant FOLFIRINOX Based Therapies in Pancreatic, Colon and Appendiceal Cancers (CENDIFOX)
- Outcome
- Outcome unknown
- Phase
- Phase 1 / Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- 20 October 2021
- Expected end
- September 2026
- Enrollment
- 50 participants
- Sites
- 3
- Primary outcomes
- Drug Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
- Sponsor
- Other
- Results posted
- No
- Last update
- 17 December 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers